Recent Company News

• 06:50 AM ET Oct 29, 2025
  

  Orion upgraded to buy from accumulate at OP Corporate Bank (pre-European open) (€63.00, +2.00)

• 09:18 AM ET Oct 28, 2025
  

  Transcript Intelligence: Orion Q3 Earnings Themes (€62.60, -5.60)

• 06:04 AM ET Oct 28, 2025
  

  Orion reports Q3 EPS €0.68 vs FactSet €0.69 [7 est, €0.62-0.76]; narrows FY25 outlook (€66.45, -1.75)

• 08:32 AM ET Oct 23, 2025
  

  Orion, Abzena announce exclusive commercial license for Abzena's antibody (€68.05, +0.55)

• 07:11 AM ET Oct 18, 2025
  

  Celcuity presents updated data from Phase 1 trial evaluating gedatolisib in combination with Nubeqa in men with mCRPC ($51.96, 0.00)

• 05:11 AM ET Oct 06, 2025
  

  Celltrion presents positive real-world data on the use of subcutaneous infliximab at MTE Sessions at UEG 2025 (KRW 175400.0000, 0)

• 04:09 AM ET Oct 06, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:35 AM ET Oct 06, 2025
  

  Orion upgraded to buy from hold at Nordea (€65.30, 0.00)

• 06:07 AM ET Sep 30, 2025
  

  Orion's phase 2 study of ODM-105 in insomnia did not meet primary goal (€63.75, -0.70)

• 12:50 PM ET Sep 26, 2025
  

  White House says the latest pharmaceutical tariffs do not apply to countries with negotiated trade deals -- wires